Rezolute Posts $18.5M Q1 Loss as Cash Drops to $90.0M Ahead of December upLIFT Data
RZLT has more than doubled off its 52-week low of $1.07.
Summary
Rezolute reported a $18.5M first-quarter fiscal 2027 net loss, with cash down to $90.0M from $107.8M, while confirming upLIFT topline data are due mid-December 2026.
Key Events · Earnings and Guidance · RZLT
-
Q1 FY2027 Net Loss of $18.5M
For the quarter ended September 30, 2026, the net loss was $18.5 million versus $18.2 million a year earlier. R&D fell to $12.8 million from $13.1 million, and G&A to $6.6 million from $6.7 million.
-
Cash Falls to $90.0M
Cash, cash equivalents and marketable securities totaled $90.0 million at September 30, 2026, down from $107.8 million at June 30, 2026, a $17.8 million quarterly burn.
-
upLIFT Topline Due Mid-December 2026
Enrollment in the Phase 3 tumor HI study is complete, with topline results expected by mid-December 2026; 7 of the first 8 participants met the responder criterion.
-
BLA Submission Targeted for 2027
Following the FDA-recommended pre-BLA meeting, the company plans to submit a BLA for ersodetug in one or potentially both indications in 2027.
Analysis · RZLT · Life Sciences
The quarter itself was unremarkable: a $18.5M net loss against $18.2M a year ago, with spending essentially flat. What matters is the cash line. At September 30, cash stood at $90.0M versus $107.8M at June 30, a $17.8M burn in three months. At the current pace that is roughly five quarters of runway, enough to cover the mid-December 2026 upLIFT topline readout and the planned 2027 BLA submission, but it leaves little room for a commercial build-out without new capital. The clinical narrative is unchanged from prior filings: upLIFT enrollment is complete with topline guided to mid-December 2026, and the sunRIZE miss in congenital HI is being worked around via an FDA-recommended pre-BLA meeting. The company also flagged a preliminary proxy seeking 60 million additional authorized shares, a reminder that financing is already being prepared.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RZLT was trading at $3.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $352.1M. The 52-week trading range was $1.07 to $11.46. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.